Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$3.91 USD
+0.03 (0.77%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $3.92 +0.01 (0.26%) 4:52 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EDIT 3.91 +0.03(0.77%)
Will EDIT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for EDIT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EDIT
Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound?
CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?
EDIT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down
Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates
Illumina (ILMN) Q2 Earnings and Revenues Top Estimates
Other News for EDIT
Editas Medicine, Inc. (EDIT) 2024 Cantor Global Healthcare Conference (Transcript)
Where Editas Medicine Stands With Analysts
Buy Rating Initiated for Editas Medicine Citing Superior Editing Platform and Market Potential
Editas Medicine initiated with bullish view at JonesResearch, here's why
Editas Medicine, Inc. (EDIT) Presents at Wells Fargo 2024 Healthcare Conference (Transcript)